-
-
[1]Cacoub P, Costedoat-Chalumeau N, Lidove O, et al.Cryoglobu-linemia vascultis[J].Curr Opin Rheumatol, 2002, 14∶29-35. [2]D'Amico G.Renal involvement in hepatitis C infection:cryoglobu-linemic glomerulonephritis[J].Kidney Int, 1998, 54∶650-671. [3]Morales J, Morales E, Andres A, et al.Glomerulonephritis associat-ed with hepatitis C virus infection[J].Curr Opin Nephrol Hypertens, 1999, 8∶205-211. [4]Stehman-breen C, Alpers CE, Fleet WP, et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus[J].Nephron, 1999, 81∶37-40. [5]Johnson RJ, Gretch DR, Couser WG, et al.Hepatitis C virus-asso-ciated glomerulonephritis.Effect of alpha-intenferon therapy[J].Kidney Int, 1994, 46∶1700-1704. [6]Baid S, Pascual M, Williams Jr WW, et al.Renal thrombotic mi-croangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients[J].J Am Soc Nephrol, 1999, 10∶146-153. [7]Markowitz GS, Cheng JT, Colvin RB, et al.Hepatitis C viral infec-tion is associated with fibrillary glomerulonephritis and immunotactoidglomerulopathy[J].J Am Soc Nephrol, 1998, 9∶2244-2252. [8]Tarantino A, Campise M, Banfi G, et al. long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis[J].Kidney In, 1995, 47∶618-623. [9]Chadban SJ, Atkins RC. Glomerulonephritis[J].Lancet, 2005, 365∶1797-1806. [10]Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus[J].N Engl J Med, 1994, 330∶751-756. [11]Sabry AA, Sobh MA, Sheaashaa HA, et al. Effect of combination therapy (ribavrin and interferon) in HCV-related glomerulopathy[J].Nephrol Dial Transplant, 2002, 17∶1924-1930. [12]Brunchfeld A, Lindahl K, Stahle L, et al. Intrferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency[J].Nephrol Dial Transplant, 2003, 18∶1573-1580. [13]Rossi P, Bertani T, Baio P, et al.Hepatitis C virus-related cryo-globulinemic glomerulonephitis:long-term remission after antiviraltherapy[J].Kidney Int, 2003, 63∶2236-2241. [14]Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN[J].Am J Kidney Dis, 2004, 43∶617-623. [15]Hu S1, Jaber BL.Ribavirin monotherapy for hepatitis C virus-as-sociatedmembranous nephropathy[J].Clin Nephrol, 2005, 63∶41-45. [16]Kamar N, Sandres-saune K, Selves J, et al. Long-term ribavirin therapy in function and liver histology[J].Am J Kidney Dis, 2003, 42∶184-192. [17]Pham HP, Feray C, Samuel D, et al.Effects of ribavirin on hepa-tits C-associated nephritic syndrome in four liver transplant recipi-ents[J].Kidney Int, 1998, 54∶1311-1319. [18]Kamar N, Chatelut E, Manolis E, et al.Ribavirin pharmacokinet-ics in renal and liver transplant patients:evidence that it depends onrenal function[J].Am J Kidney Dis, 2004, 43∶140-146. [19]Fabrizi F, Colucci P, Ponticelli F. Kidney and liver involvement in cryoglobulinemia[J].Semin Nephrol, 2002, 22∶309-318. [20]Zaja F, De Vita S, Mazaro C, et al.Efficacy and safety of ritux-imab in typeⅡmixed cryoglobulinemia[J].Blood, 2003, 101∶3827-3834. [21]Roccatello D, Baldovino S, Rossi D, et al.Long-term effects ofanti-CD20 monoclonal antibody treatment of cryoglobulinaemic glo-merulonephritis[J].Nephrol Dial Transplant, 2004, 19∶3054-3061. [22]Base G, Ribers D, Kamar N, et al.Riruximab therapy for de novomixed cryoglobullinmia in renal-transplant patients[J].Transplan-tation (in press) .
本文二维码
计量
- 文章访问数: 2100
- HTML全文浏览量: 8
- PDF下载量: 849
- 被引次数: 0